The enrolled studies indicated that early PPAR-γ agonist intervention is beneficial for patients, and that high-dose PPAR-γ therapy may have a better clinical effect, especially in the reversing the effects of cognitive impairment. This evidence concerns the gene PPARG and Cognitive impairment.